Danaher Corporation showcases a steady yet modest dividend profile, making it a notable choice for investors seeking consistent income. With its near half-percent yield and a robust 33-year history of uninterrupted dividends, Danaher projects strong reliability without recent cuts. Coupled with a solid payout ratio, the company aligns with long-term dividend-focused strategies.
Detail | Information |
---|---|
Sector | Life Sciences |
Dividend Yield | 0.55% |
Current Dividend Per Share | 1.05 USD |
Dividend History | 33 years |
Last Cut or Suspension | None |
Danaher's 33-year streak of unbroken dividend payments underscores its commitment to shareholders. Such a track record often represents a stable company with predictable cash flows, vital for income-focused investors.
Year | Dividend Per Share (USD) |
---|---|
2025 | 0.32 |
2024 | 1.08 |
2023 | 0.99 |
2022 | 0.89 |
2021 | 0.74 |
Observing Danaher's dividend growth over recent years highlights its capability to enhance shareholder returns. The incremental rises in both 3-year and 5-year growth rates reflect the company’s focus on rewarding its investors progressively.
Time | Growth |
---|---|
3 years | 13.19% |
5 years | 12.37% |
The average dividend growth is 12.37% over 5 years. This shows moderate but steady dividend growth.
A payout ratio provides insight into how much of a company’s earnings are distributed as dividends. Danaher reflects a conservative approach with an EPS-based payout ratio of 20% and an FCF ratio of 15%, indicating ample retained earnings for reinvestment.
Ratio | Percentage |
---|---|
EPS-based | 20% |
Free cash flow-based | 15% |
Analyzing a company's cash flow and capital usage reveals its operational efficiency and investment capability. Danaher demonstrates a balanced approach with strong yields and capital reinvestment ratios, underpinning capital-intensive growth strategies.
2024 | 2023 | 2022 | |
---|---|---|---|
Free Cash Flow Yield | 3.16% | 3.39% | 4.32% |
Earnings Yield | 2.32% | 2.80% | 4.23% |
CAPEX to Operating Cash Flow | 21.54% | 19.30% | 13.52% |
Stock-based Compensation to Revenue | 1.21% | 1.28% | 0.94% |
Free Cash Flow / Operating Cash Flow Ratio | 79.19% | 80.70% | 86.48% |
The state of a company’s balance sheet indicates its financial flexibility and risk management ability. Danaher's prudent leverage and healthy ratios point to robust financial stewardship amidst operational demands.
2024 | 2023 | 2022 | |
---|---|---|---|
Debt-to-Equity | 0.32 | 0.37 | 0.39 |
Debt-to-Assets | 0.21 | 0.23 | 0.23 |
Debt-to-Capital | 0.24 | 0.27 | 0.28 |
Net Debt to EBITDA | 2.18 | 1.82 | 1.41 |
Current Ratio | 1.43 | 1.68 | 1.89 |
Quick Ratio | 1.05 | 1.37 | 1.52 |
Financial Leverage | 1.57 | 1.58 | 1.68 |
Profitability metrics offer insights into operational efficiency and market competitiveness. Danaher showcases strong profitability margins paired with excellent ROE and ROA, indicating effective utilization of resources.
2024 | 2023 | 2022 | |
---|---|---|---|
Return on Equity | 7.87% | 8.91% | 14.39% |
Return on Assets | 5.03% | 5.64% | 8.55% |
Net Margin | 16.33% | 19.94% | 22.91% |
EBIT Margin | 20.37% | 22.31% | 23.35% |
EBITDA Margin | 20.37% | 31.39% | 30.86% |
Gross Margin | 59.50% | 58.74% | 60.21% |
Research & Development to Revenue | 6.70% | 6.29% | 5.54% |
Criteria | Description | Score |
---|---|---|
Dividend Yield | A modest yield contributing steady income. | |
Dividend Stability | Reliability without disruptions. | |
Dividend Growth | Steady increase over five years. | |
Payout Ratio | Conservative and sustainable distribution. | |
Financial Stability | Demonstrates strong balance sheet management. | |
Dividend Continuity | Consistency with no recent interruptions. | |
Cashflow Coverage | Solid cash reserves supporting payouts. | |
Balance Sheet Quality | Robust financial health metrics. |
Danaher Corporation earns a solid dividend reliability and growth potential score, thereby reinforcing its image as a stable long-term investment. Its low yield reflects its focus on reinvestment and growth rather than high payouts, suiting patient investors with a preference for steady portfolio expansion.